Cellumed Co.,Ltd. (KOSDAQ:049180)

Market Cap	83.94B -19.5%
Revenue (ttm)	140.19B +8.6%
Net Income	-2.24B
EPS	-41.00
Shares Out	83.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,744,448
Average Volume	1,769,414
Open	1,111.00
Previous Close	1,110.00
Day's Range	950.00 - 1,126.00
52-Week Range	542.00 - 2,975.00
Beta	1.56
RSI	39.32
Earnings Date	May 15, 2026

About Cellumed

Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFβ-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone ...

• Industry: Business Services, not elsewhere classified
• Founded: 1985
• Employees: 90
• Stock Exchange: KOSDAQ
• Ticker Symbol: 049180

Financial Performance

In 2025, Cellumed's revenue was 140.19 billion, an increase of 8.56% compared to the previous year's 129.14 billion. Losses were -2.24 billion, -92.91% less than in 2024.